Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Income from Continuing Operations (2020 - 2025)

Vivos Therapeutics has reported Income from Continuing Operations over the past 6 years, most recently at 6954000.0 for Q4 2025.

  • Quarterly Income from Continuing Operations fell 145.99% to 6954000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 21231000.0 through Dec 2025, down 90.65% year-over-year, with the annual reading at 21230000.0 for FY2025, 90.64% down from the prior year.
  • Income from Continuing Operations was 6954000.0 for Q4 2025 at Vivos Therapeutics, down from 5400000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 17856000.0 in Q4 2022 and troughed at 6992000.0 in Q2 2022.
  • The 5-year median for Income from Continuing Operations is 3953500.0 (2021), against an average of 2291600.0.
  • The largest YoY upside for Income from Continuing Operations was 306.13% in 2021 against a maximum downside of 197.29% in 2021.
  • A 5-year view of Income from Continuing Operations shows it stood at 12914000.0 in 2021, then surged by 38.27% to 17856000.0 in 2022, then crashed by 123.85% to 4259000.0 in 2023, then surged by 33.62% to 2827000.0 in 2024, then crashed by 145.99% to 6954000.0 in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Income from Continuing Operations are 6954000.0 (Q4 2025), 5400000.0 (Q3 2025), and 5013000.0 (Q2 2025).